We are very pleased to share the first study characterizing the criteria of the Royal Legislative Decree 1/2015 for the reimbursement of new medicines in Spain, performed by an expert panel with broad experience on drug evaluation and decision-making in Spain.
The study, which Omakase is co-author, is published in the International Journal of Technology Assessment in Health Care and is available here: https://www.cambridge.org/core/journals/international-journal-of-technology-assessment-in-health-care/article/feasibility-study-to-characterize-price-and-reimbursement-decisionmaking-criteria-for-the-inclusion-of-new-drugs-in-the-spanish-national-health-system-the-cefiderocol-example/C9217EFB97145ADBA6217B3D51B33BD5